Literature DB >> 33388011

Highlights on Medical Treatment of Uterine Fibroids.

Stefano Angioni1, Maurizio N D'Alterio1, Angelos Daniilidis2.   

Abstract

Uterine fibroids (leiomyomas or myomas) are the most frequent benign tumors in women. Heavy menstrual bleeding with resultant anemia, dysmenorrhea, chronic pelvic pain, infertility urinary symptoms and constipation are generally associated with uterine fibroids (UFs). Although strategies mainly resort to surgical intervention, medical treatments are considered the first-line treatment to preserve fertility and avoid surgery. The aim of this review is to offer available and newest medical treatment options for symptomatic UFs. Various medical therapies are now available for women with uterine fibroids, although each therapy has its own advantages and disadvantages. Our topic specifically explores gonadotropin-releasing hormone (GnRH) analogs and selective progesterone receptor modulators (SPRMs), but also provides the reader with useful advice on the therapies for fibroids available after the recent European Medicines Agency (EMA) warning (EMA/160220/2020). The treatment options depend on the personal treatment objectives of the patients, in addition to treatment effectiveness and necessity for recurrent interventions. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Uterine fibroids; elagolix; gonadotrophin-releasing hormonezzm321990agonists; gonadotrophin-releasing hormone antagonists; medical therapy; selective progesterone receptor modulators; ulipristal acetate; vilaprisan.

Year:  2021        PMID: 33388011     DOI: 10.2174/1381612826666210101152820

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  7 in total

1.  Transumbilical single-site laparoscopic parallel mattress suturing prevents bleeding and chronic pelvic pain in myomectomy: a retrospective cohort study of 124 cases with intramural fibroids.

Authors:  Xi Zeng; Lin Li; Hui Ye; Mingrong Xi
Journal:  BMC Surg       Date:  2022-05-13       Impact factor: 2.030

Review 2.  Macrophages and Immune Responses in Uterine Fibroids.

Authors:  Alessandro Zannotti; Stefania Greco; Pamela Pellegrino; Federica Giantomassi; Giovanni Delli Carpini; Gaia Goteri; Andrea Ciavattini; Pasquapina Ciarmela
Journal:  Cells       Date:  2021-04-22       Impact factor: 6.600

3.  An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

Authors:  Mohamed Ali; Hsin-Yuan Chen; Yi-Fen Chiang; Osama A Badary; Shih-Min Hsia; Ayman Al-Hendy
Journal:  Expert Opin Pharmacother       Date:  2022-01-24       Impact factor: 3.889

4.  Risk of uterine leiomyoma based on BET1L rs2280543 single nucleotide polymorphism and vegetarian diet.

Authors:  Shan Chih Lee; Ying-Hsiang Chou; Disline Manli Tantoh; Shu-Yi Hsu; Oswald Ndi Nfor; Yeu Sheng Tyan; Yung-Po Liaw
Journal:  BMC Womens Health       Date:  2022-04-27       Impact factor: 2.742

5.  Successful laparoscopic management of acute abdominal pain due to spontaneous rupture of subserosal vessels overlying a uterine fibroid: a case report and surgical video.

Authors:  Shigeru Fujita; Kuniaki Ota; Toshimitsu Maemura; Noriko Morita; Keiichi Furusawa; Kayo Mitamura; Kenji Nishizawa
Journal:  BMC Womens Health       Date:  2022-09-23       Impact factor: 2.742

Review 6.  Efficacy of Low-Dose Estrogen-Progestins and Progestins in Japanese Women with Dysmenorrhea: A Systematic Review and Network Meta-analysis.

Authors:  Masaru Iwata; Yoshihiro Oikawa; Yutaka Shimizu; Naotaka Sakashita; Ayako Shoji; Ataru Igarashi; Yutaka Osuga
Journal:  Adv Ther       Date:  2022-09-01       Impact factor: 4.070

Review 7.  Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

Authors:  Mohamed Ali; Sara A R; Ayman Al Hendy
Journal:  Expert Rev Clin Pharmacol       Date:  2021-03-15       Impact factor: 5.045

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.